PNH - Alexion

Spark Up worked closely along side Alexion Pharmaceuticals in their fight to create access for Australians in need of a life saving drug - Soliris, for the treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH), a very rare and debilitating disease of the bone marrow that affects the blood and major organs. We provided targeted direct mail pieces with relevant facts and information about the disease to identified Hematologists and other relevant HCP’s. Our design team managed the execution of the global branding guidelines across their industry trade publications, print and promotion materials and assisted with the organization of key note speaker meetings. The result was in January 2011, Australian PNH sufferers gained access to the life saving Soliris treatment we continue to service their marketing team and patient support programmes.